Combination therapy with the new ACE inhibitor moexi-−17.6 mm Hg/−12.8 mm Hg and −17.2 mm Hg/−13.9 mm Hg in the moexipril/HCTZ and metoprolol/HCTZ pril plus hydrochlorothiazide (HCTZ) results in significant blood pressure (BP) reductions. This study comgroups, respectively. The response rate to both kinds of combinations were very similar, 69% and 74% in the pares the efficacy and safety of moexipril plus HCTZ to that of a standard combination treatment in patients moexipril/HCTZ and metoprolol/HCTZ groups, respectively. The percentage of patients which experienced one with mild-to-moderate hypertension.
Introduction
induced by the thiazides. 8 
Fixed dose antihypertensive combinations are
This study was designed to compare the efficacy increasingly being used in the management of and safety of the combination of the new ACEhypertension. These usually combine drugs with inhibitor moexipril plus hydrochlorothiazide to the different mechanisms of action which offer the combination of metoprolol plus hydrochlorothiazpotential for a synergistic effect on blood pressure ide in the treatment of mild-to-moderate hyperten-(BP) while counteracting the side effects of each sives. other.
Numerous studies have shown the efficacy of a
Patients and methods
combination of a beta-blocker with a diuretic, for example metoprolol plus hydrochlorothiazide, in Patients lowering BP. The hypotensive effects of both are One hundred and forty men and women with a sitfully additive. In addition, diuretics and beta-blockting diastolic blood pressure (DBP) of 95-114 ers have been shown to reduce morbidity and mormm Hg were considered for entry into the study if tality in hypertensive subjects when used alone or aged between 35 and 80 years. Patients had to be in combination. [1] [2] [3] [4] The combination of an ACEgenerally healthy and free of secondary hyperteninhibitor with a diuretic is increasingly popular. sion, cardiac disease or a significant impairment of Addition of even small doses of a thiazide diuretic renal or hepatic function. to an ACE-inhibitor has shown far greater additional falls in BP than could be achieved by substantial increases in the ACE-inhibitor dose. [5] [6] [7] Furthermore, Conduct of the study a potential benefit of this combination is that ACEAfter providing informed consent eligible patients entered a 4-week single-blind placebo run-in phase. into one of two treatment regimens:
(1) 7.5 mg moexipril combined with 12.5 mg hyd-HCTZ combination group. A total of 127 (91%) patients completed the double-blind period of the rochlorothiazide (HCTZ); (2) 100 mg metoprolol combined with 12.5 mg study and 13 (9%) were prematurely withdrawn for adverse events. HCTZ.
The majority of the patients were men (56%). The The study drugs, contained in capsules for moexiaverage age was 59 years and 69% of the patients pril and hydrochlorothiazide or matching placebo were under 65 years of age. There were no clinically and in tablets for metoprolol or matching placebo, relevant differences among treatment groups in any were taken once daily (approximately at the same baseline demographic variables (see Table 1 ). time of the day) over a 12-week double-blind treatment period. Compliance was assessed by pill counEfficacy ting.
BP was measured by trained personnel using stan- Figures 1 and 2 show the changes in sitting systolic dard mercury sphygmomanometers. Trough BP and DBP in both treatment groups from baseline to measurements were obtained at each visit (at the endpoint (last valid BP measurement during the end of the 22-26 hour dosing interval before drug double-blind phase). Treatment means at baseline administration). The mean of three sitting readings were very similar: 101.7 mm Hg and 101.5 mm Hg taken 1 min apart was used as the visits sitting BP.
in the moexipril combination group and the metopAfterwards, patients were asked to get up and an rolol combination group, respectively. With respect immediate upon standing and two 2-min standing to adjusted mean reductions from baseline in sitting BP readings were taken. Heart rate was measured in DBP at endpoint (−12.8 mm Hg vs −13.9 mm Hg), no the sitting and 2-min standing position.
statistically significant difference was shown The primary variable of efficacy was based on the between the 7.5 mg moexipril/12.5 mg HCTZ combimean change from baseline in sitting DBP at the end nation group and the 100 mg metoprolol/12.5 mg of the 12-week double-blind treatment. Sitting sys-HCTZ combination group. Comparable results were tolic BP (SBP) and standing DBPs were recorded as obtained at 1 and 2 h after the initial dose and at all secondary efficacy variables. trough timepoints. Adverse experiences (AEs) as well as pre-vs postExploratory analysis of subgroups showed similar treatment results of physical examination, electroresults between the treatment groups among both cardiogram and laboratory tests (biochemistry, hemmen and women, younger patients (Ͻ65 years) and atology and urinalysis) were included in the safety older patients (у65 years) and mild and moderate evaluation. Adverse events were assessed at each hypertensive patients. visit by questioning in a general way. The adverse At endpoint, 69% of the patients showed a good events were graded by the investigator as serious or (sitting DBP у90 mm Hg but reduction of у10 non-serious, as mild, moderate or severe and the mm Hg from baseline) or excellent (sitting DBP Ͻ90 relationship to the study medication was characmm Hg) response to treatment in the moexipril plus terized as none, likely, possible, probable or HCTZ group compared to 74% of the patients in the highly probable.
metoprolol plus HCTZ group. The difference was not statistically significant. Changes in sitting SBP paralleled those seen in Statistical analysis DBP and changes in systolic and DBP in the standAn intent to treat analysis which included all raning and 2-min standing position were similar to domized patients who had at least one baseline BP those in the sitting position. No statistically signifireading and one post baseline reading was perforcant differences between the moexipril and the med to assess efficacy. All randomized patients were metoprolol combination group were detected in included into the safety analysis. The BP data were reducing the sitting SBP (−17.6 mg Hg vs −17.2 analyzed using a two-way analysis of covariance mm Hg) and the standing BP. (ANCOVA). Before utilizing the final ANCOVA model, it was established that generally there were Safety no significant treatment-by-baseline interactions. Therefore the final model included only the main Both combination treatments were generally well effects for treatment and investigator, with the basetolerated and no unusual or unexpected adverse line measurement of BP as the covariate. The incievents occurred during the study. The incidence of dence of adverse events was summarized for each patients reporting at least one AE (regardless of drug treatment group in frequency tables and demorelationship) was 46% in the moexipril/HCTZ and graphic and baseline characteristics were summar-61% in the metoprolol/HCTZ combination group, ized using descriptive statistics.
respectively. Table 2 is a summary of the most frequently reported AEs. Few of these AEs were considered drug related by the investigators. Cough was
Results
the most frequently reported adverse event that was considered related to moexipril combination treatOf 155 patients initially enrolled, 140 met the entry criteria and were randomized to treatment. Of the ment (7%) and fatigue, dizziness and headache were the most common AEs assessed to be at least poss-140 patients, 69 (49%) were randomized to the 7.5 mg moexipril/12.5 mg HCTZ combination group ibly related to treatment with the metoprolol combination (7% each). and 71 (51%) to the 100 mg metoprolol/12.5 mg Thirteen patients were discontinued due to AEs Atrial fibrillation (see Table 3 ). Of these patients two were receiving bine high efficacy with a good safety profile. Therefore, the fact that ACE inhibitors are reported to be mm Hg; atrial fibrillation).
There were no clinically significant changes nearly metabolically neutral seems to be advantageous while this is not true for HCTZ or metoprobetween pre-and post-treatment results of physical examination, electrocardiogram or laboratory lol. [20] [21] [22] Hypokalaemia, hyponatraemia, hypochloraemia or hypercalcaemia as well as increases in values, however elevated uric acid levels were reported in six patients (8.7%) in the moexipril comserum glucose, cholesterine, triglycerides and uric acid are the metabolic disturbances often seen with bination group and in 10 patients (14.3%) in the metoprolol combination group. All of these patients HCTZ. [23] [24] [25] [26] [27] As the dosage of HCTZ was very low in this study the metabolic changes seen after 12 weeks had at least one uric acid abnormality that was outside predefined limits. None of these events was of treatment were small and only rarely classified as clinically significant. Although no statistically difconsidered clinically important by the investigators.
ference could be detected between the two groups fewer patients in the moexipril combination group Discussion reported noteworthy changes in one of the above mentioned metabolic parameters. Furthermore Despite the availability of numerous single antihypertensive agents, combination therapy is required moexipril seemed to be more able than metoprolol to counterbalance the negative effects of HCTZ. in many patients to achieve BP control. As the doseresponse curve for antihypertensive agents tends to Overall, adverse experiences occurred in 61% and 46% of the patients in the metoprolol and moexipril plateau at higher doses, titration toward maximum doses of a single agent often leads to only small groups, respectively. Especially peripheral vascular disease, dyspepsia, nausea, dizziness, rash and tinincreases in efficacy at the expense of an undesirable increase in side effects. 9 Alternatively, adding of a nitus were reported much more frequent in the metoprolol group causing a higher incidence of AEs second drug from another class with a different mode of action seems to be more recommended if in the cardiovascular system, the digestive system, the musculoskeletal system, the nervous system, as initial therapy is inadequate. 10 This study compared the efficacy and safety of two antihypertensive comwell as in the system of skin and appendages and special senses. As for other ACE inhibitors [28] [29] [30] [31] binations, the new ACE inhibitor moexipril combined to HCTZ and metoprolol combined to HCTZ. cough was the adverse experience which was reported most frequently in the moexipril group. The principal finding was that both combinations were equivalent in their effectiveness in reducing Ten per cent of patients reported cough in the moexipril group compared to only 4% in the metoprolol BP and that moexipril plus HCTZ was as safe as the metoprolol combination.
group, but none of the patients had to discontinue from treatment because of this AE. The results confirmed that both fixed combinations administered at a daily dosage of 7.5 mg
In conclusion, this study comparing the efficacy and safety of moexipril plus HCTZ to that of metopmoexipril plus 12.5 mg HCTZ and 100 mg metoprolol plus 12.5 mg HCTZ were able to decrease both rolol plus HCTZ during a 12-week treatment period indicates that the moexipril combination is as effecsitting DBP and sitting SBP for 24 h. Reduction in sitting SBP and sitting DBP after 12 weeks of treattive as the metoprolol combination in treating mildto-moderate hypertensives. As to be seen from studment were −17.6/−12.8 mm Hg and −17.2/−13.9 for the moexipril and metoprolol combination groups, ies with diuretics and beta-blockers an important effect of this BP lowering activity is a reduced risk respectively. Both combinations also achieved a high and comparable good (sitting DBP у90 mm Hg of cardiovascular diseases, stroke, heart attacks and heart failure. Although up to now there are no data but reduction of у10 mm Hg from baseline) or excellent (sitting DBP Ͻ90 mm Hg) BP response of 69% available whether ACE inhibitors may also reduce morbidity and mortality in hypertensive patients, in the moexipril combination group and 74% in the metoprolol combination group. These values are in this short-term study showed that the combination of moexipril plus HCTZ has a good safety profile and accordance with BP reductions and responses seen with other combinations [11] [12] [13] [14] and the values are was as safe as metoprolol plus HCTZ. clearly higher than those seen in patients treated with moexipril, metoprolol or HCTZ alone. [15] [16] [17] [18] [19] 
